EUVIMEDEUVIMED entdecken
Open Access

Feasibility of epidermal growth factor receptor and Kirsten rat sarcoma viral oncogene homolog mutation testing in non-plasma body fluids with low tumor cellularity using Idylla®: A proof-of-concept

Aida Molero iD, Pilar Ortega De la Obra, Monica Mate, María Purificación Manzanares

Cytojournal · 29.07.2026 · 23 · 46

DOI: 10.25259/cytojournal_160_2025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cytojournal, online erschienen am 29.07.2026. Verfasst von Aida Molero und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hospital Universitario Río Hortega, Valladolid, Spain. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This retrospective, single-center, small-sample proof-of-concept study aims to evaluate the feasibility of detecting epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in the supernatant of non-plasma biological fluids, pleural, ascitic, or pericardial effusions, using the Idylla® platform (Ct cartridges with research use only certification for plasma samples). Materials and Methods: Ten fluids were tested with the Ct KRAS cartridge and seven with the Ct EGFR cartridge, comparing results with Idylla® testing in formalin fixed paraffin embedded (FFPE) tissue from the primary tumor. For each sample, 100 μL of supernatant was directly pipetted into the corresponding cartridge; in turbid samples, a preliminary centrifugation step (1600 g, 10 min, room temperature) was performed.

Results

All cases showed concordance between fluid and FFPE results. Notably, KRAS mutations were detected in two fluids with no malignant cells and in one with only scattered tumor cells, and an EGFR mutation was detected in a sample with 5% tumor cells. Specimens had been stored at 4°C for up to 3 weeks, suggesting good DNA preservation.

Conclusion

This simple and rapid approach appears feasible in low tumor cellularity samples and could expand molecular testing to patients without accessible tissue. Validation in larger, multicenter cohorts is warranted.

Schlagwörter

Stichwörter der Autor:innen

Epidermal growth factor receptor mutationsIdylla® platformKirsten rat sarcoma viral oncogene homolog mutationsLiquid biopsyNon-plasma biological fluids

Autor:innen und Institutionen

  • Department of Pathology, Hospital Universitario Río Hortega, Valladolid, Spain.
  • Department of Pathology, Hospital General de Segovia, Segovia, Spain.

ORCID-Profile: Aida Molero

Zitieren

APA

Molero, A., De la Obra, P. O., Mate, M., & Manzanares, M. P. (2026). Feasibility of epidermal growth factor receptor and Kirsten rat sarcoma viral oncogene homolog mutation testing in non-plasma body fluids with low tumor cellularity using Idylla®: A proof-of-concept. Cytojournal, 23, 46. https://doi.org/10.25259/cytojournal_160_2025

Vancouver

Molero A, De la Obra PO, Mate M, Manzanares MP. Feasibility of epidermal growth factor receptor and Kirsten rat sarcoma viral oncogene homolog mutation testing in non-plasma body fluids with low tumor cellularity using Idylla®: A proof-of-concept. Cytojournal. 2026;23:46. doi:10.25259/cytojournal_160_2025

BibTeX
@article{Molero2026,
  author = {Molero, Aida and De la Obra, Pilar Ortega and Mate, Monica and Manzanares, María Purificación},
  title = {Feasibility of epidermal growth factor receptor and Kirsten rat sarcoma viral oncogene homolog mutation testing in non-plasma body fluids with low tumor cellularity using Idylla®: A proof-of-concept},
  journal = {Cytojournal},
  year = {2026},
  volume = {23},
  pages = {46},
  doi = {10.25259/cytojournal_160_2025}
}
Kostenlos starten →